



Short version of press release from Emotra AB
Gothenburg June 27, 2013

Communiqué from Emotra's Annual General Meeting

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

During the AGM, the following decisions were made;

Income statement, balance sheet and proposed disposition were adopted. The members of the Board and the President were discharged of liability.

The Board members Margit Ferm, Lars-Håkan Thorell and Claes Holmberg were re-elected. Roy Jonebrant was elected as a new member of the Board.

The Annual meeting decided to elect Thomas Nilsson, at Ernst & Young AB as auditor.

A decision was made on a total remuneration for the board of 120.000 SEK for this year.

The Board was authorized to decide on issues of new shares, to be carried out not later than at the date of the next Annual General Meeting and not more than 420 000 new shares and not below 7,20 SEK per shares and without right of priority for the shareholders.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se